Publications

Found 42 results
Filters: First Letter Of Last Name is W  [Clear All Filters]
2011
Beltran H, Rickman DS, Park K, Chae SSuk, Sboner A, MacDonald TY, Wang Y, Sheikh KL, Terry S, Tagawa ST et al..  2011.  Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets.. Cancer Discov. 1(6):487-95.
2009
Mosquera J-M, Mehra R, Regan MM, Perner S, Genega EM, Bueti G, Shah RB, Gaston S, Tomlins SA, Wei JT et al..  2009.  Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.. Clin Cancer Res. 15(14):4706-11.
Perner S, Wagner PL, Soltermann A, LaFargue C, Tischler V, Weir BA, Weder W, Meyerson M, Giordano TJ, Moch H et al..  2009.  TTF1 expression in non-small cell lung carcinoma: association with TTF1 gene amplification and improved survival.. J Pathol. 217(1):65-72.
Perner S, Wagner PL, Soltermann A, LaFargue C, Tischler V, Weir BA, Weder W, Meyerson M, Giordano TJ, Moch H et al..  2009.  TTF1 expression in non-small cell lung carcinoma: association with TTF1 gene amplification and improved survival.. J Pathol. 217(1):65-72.
Perner S, Wagner PL, Soltermann A, LaFargue C, Tischler V, Weir BA, Weder W, Meyerson M, Giordano TJ, Moch H et al..  2009.  TTF1 expression in non-small cell lung carcinoma: association with TTF1 gene amplification and improved survival.. J Pathol. 217(1):65-72.
2008
Kelly KA, Setlur SR, Ross R, Anbazhagan R, Waterman P, Rubin MA, Weissleder R.  2008.  Detection of early prostate cancer using a hepsin-targeted imaging agent.. Cancer Res. 68(7):2286-91.
Kelly KA, Setlur SR, Ross R, Anbazhagan R, Waterman P, Rubin MA, Weissleder R.  2008.  Detection of early prostate cancer using a hepsin-targeted imaging agent.. Cancer Res. 68(7):2286-91.
Perner S, Wagner PL, Demichelis F, Mehra R, Lafargue CJ, Moss BJ, Arbogast S, Soltermann A, Weder W, Giordano TJ et al..  2008.  EML4-ALK fusion lung cancer: a rare acquired event.. Neoplasia. 10(3):298-302.
Perner S, Wagner PL, Demichelis F, Mehra R, Lafargue CJ, Moss BJ, Arbogast S, Soltermann A, Weder W, Giordano TJ et al..  2008.  EML4-ALK fusion lung cancer: a rare acquired event.. Neoplasia. 10(3):298-302.
2007
Cohen RJ, Wheeler TM, Bonkhoff H, Rubin MA.  2007.  A proposal on the identification, histologic reporting, and implications of intraductal prostatic carcinoma.. Arch Pathol Lab Med. 131(7):1103-9.
2005
Rubin MA, Bismar TA, Andrén O, Mucci L, Kim R, Shen R, Ghosh D, Wei JT, Chinnaiyan AM, Adami H-O et al..  2005.  Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death.. Cancer Epidemiol Biomarkers Prev. 14(6):1424-32.
Zhao X, Weir BA, LaFramboise T, Lin M, Beroukhim R, Garraway L, Beheshti J, Lee JC, Naoki K, Richards WG et al..  2005.  Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis.. Cancer Res. 65(13):5561-70.
Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J et al..  2005.  Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.. Nature. 436(7047):117-22.
Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J et al..  2005.  Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.. Nature. 436(7047):117-22.
Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ et al..  2005.  Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression.. Cancer Cell. 8(5):393-406.
2004
Kumar-Sinha C, Shah RB, Laxman B, Tomlins SA, Harwood J, Schmitz W, Conzelmann E, Sanda MG, Wei JT, Rubin MA et al..  2004.  Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer.. Am J Pathol. 164(3):787-93.
Browne T-J, Hirsch MS, Brodsky G, Welch WR, Loda MF, Rubin MA.  2004.  Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens.. Hum Pathol. 35(12):1462-8.